tetano
Editor, Senior Moderator
Discov Med
. Jul-Aug 2021;32(165):39-45.
Clinical Features and Outcomes of Patients with COVID-19 After Discharge: A Retrospective, Multi-center Study
Qun Zhang[SUP] #[/SUP][SUP] 1 2 [/SUP], Li Zhu[SUP] #[/SUP][SUP] 3 4 [/SUP], Jian Wang[SUP] #[/SUP][SUP] 5 [/SUP], Longgen Liu[SUP] #[/SUP][SUP] 6 [/SUP], Yun Zhao[SUP] #[/SUP][SUP] 7 [/SUP], Leyang Xue[SUP] 8 [/SUP], Yang Li[SUP] 9 [/SUP], Xuebing Yan[SUP] 10 [/SUP], Juan Cheng[SUP] 11 [/SUP], Tiamin Xu[SUP] 6 [/SUP], Jiacheng Liu[SUP] 1 [/SUP], Jie Zhan[SUP] 12 [/SUP], Ruifei Xue[SUP] 12 [/SUP], Xiang-An Zhao[SUP] 13 [/SUP], Rui Huang[SUP] 5 14 [/SUP], Chuanwu Zhu[SUP] 3 4 14 [/SUP], Chao Wu[SUP] 1 5 14 [/SUP]
Affiliations
Abstract
Background: The follow-up data of discharged patients with coronavirus disease 19 (COVID-19) have not yet been fully analyzed and reported. This study aimed to evaluate the clinical features, test results, and outcomes of COVID-19 patients after discharge.
Methods: 149 COVID-19 patients with follow-up data after discharge were included. Post-hospitalization data related to clinical features and outcomes were obtained by following the patients up to 6 weeks.
Results: The COVID-19 patients were followed for a median of 28.0 days (range of 22 days to 42 days) after discharge from hospital. At the end of follow-up, four patients (2.7%) still had cough. The proportions of leukopenia and lymphopenia were 7.4% and 4.7%, respectively. The proportions of ALT, AST, and Cr abnormalities were 26.2%, 6.0%, and 0%, respectively. Abnormal chest CT was detected in 94 (63.1%) patients, including 14 (9.4%) unilateral pneumonia and 80 (53.7%) bilateral pneumonia. However, the proportion of chest CT abnormality significantly decreased compared to that at the time of admission.
Conclusions: One month after discharge, few patients with COVID-19 had clinical symptoms; however, a substantial proportion of COVID-19 patients harbored abnormal laboratory and radiological examinations. Moderately long-term medical follow-up would justifiably benefit COVID-19 patients after discharge.
. Jul-Aug 2021;32(165):39-45.
Clinical Features and Outcomes of Patients with COVID-19 After Discharge: A Retrospective, Multi-center Study
Qun Zhang[SUP] #[/SUP][SUP] 1 2 [/SUP], Li Zhu[SUP] #[/SUP][SUP] 3 4 [/SUP], Jian Wang[SUP] #[/SUP][SUP] 5 [/SUP], Longgen Liu[SUP] #[/SUP][SUP] 6 [/SUP], Yun Zhao[SUP] #[/SUP][SUP] 7 [/SUP], Leyang Xue[SUP] 8 [/SUP], Yang Li[SUP] 9 [/SUP], Xuebing Yan[SUP] 10 [/SUP], Juan Cheng[SUP] 11 [/SUP], Tiamin Xu[SUP] 6 [/SUP], Jiacheng Liu[SUP] 1 [/SUP], Jie Zhan[SUP] 12 [/SUP], Ruifei Xue[SUP] 12 [/SUP], Xiang-An Zhao[SUP] 13 [/SUP], Rui Huang[SUP] 5 14 [/SUP], Chuanwu Zhu[SUP] 3 4 14 [/SUP], Chao Wu[SUP] 1 5 14 [/SUP]
Affiliations
- PMID: 35219355
Abstract
Background: The follow-up data of discharged patients with coronavirus disease 19 (COVID-19) have not yet been fully analyzed and reported. This study aimed to evaluate the clinical features, test results, and outcomes of COVID-19 patients after discharge.
Methods: 149 COVID-19 patients with follow-up data after discharge were included. Post-hospitalization data related to clinical features and outcomes were obtained by following the patients up to 6 weeks.
Results: The COVID-19 patients were followed for a median of 28.0 days (range of 22 days to 42 days) after discharge from hospital. At the end of follow-up, four patients (2.7%) still had cough. The proportions of leukopenia and lymphopenia were 7.4% and 4.7%, respectively. The proportions of ALT, AST, and Cr abnormalities were 26.2%, 6.0%, and 0%, respectively. Abnormal chest CT was detected in 94 (63.1%) patients, including 14 (9.4%) unilateral pneumonia and 80 (53.7%) bilateral pneumonia. However, the proportion of chest CT abnormality significantly decreased compared to that at the time of admission.
Conclusions: One month after discharge, few patients with COVID-19 had clinical symptoms; however, a substantial proportion of COVID-19 patients harbored abnormal laboratory and radiological examinations. Moderately long-term medical follow-up would justifiably benefit COVID-19 patients after discharge.
